AMPK-activation by Metformin in FSGS: AMP-FSGS

NCT06090227 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Focal Segmental Glomerulosclerosis

Interventions

DRUG: Metformin + Standard of Care
OTHER: Placebo + Standard of Care

Sponsor

Yale University

Collaborators

[object Object]